Derivation of megakaryocytes and platelets from human pluripotent stem cells

Yanfeng Li, Ying Wang, Linzhao Cheng, Zack Z. Wang

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Megakaryocytes (MKs), rare hematopoietic cells in adult bone marrow, produce platelets that are critical to vascular hemostasis and wound healing. Ex vivo generation of MKs from human induced pluripotent stem cells (hiPSCs) provides a renewable cell source of platelets for treating thrombocytopenic patients and allows a better understanding of MK/platelet biology. The key requirements in this approach include developing a robust and consistent method for the production of functional progeny cells, such as MKs from hiPSCs, and minimizing risk and variation due to the animal-derived products in cell cultures. Here, we describe an efficient system to generate MKs from hiPSCs under a feeder-free and xeno-free condition, in which all the animal-derived products were eliminated. Several crucial reagents were evaluated and replaced with FDA-approved pharmacological reagents, including romiplostim (Nplate®, a thrombopoietin analog), Oprelvekin (recombinant IL-11), and Plasbumin (human albumin). This basic and defined differentiation system provides a platform for our future effort in investigation of regulatory factors and protocol optimization toward generating large numbers of platelets ex vivo.

Original languageEnglish (US)
Title of host publicationHematopoietic Differentiation of Human Pluripotent Stem Cells
PublisherSpringer Netherlands
Pages41-50
Number of pages10
ISBN (Print)9789401773126, 9789401773119
DOIs
StatePublished - Aug 25 2015

Fingerprint

Pluripotent Stem Cells
Megakaryocytes
Platelets
Stem cells
Blood Platelets
Induced Pluripotent Stem Cells
oprelvekin
Animals
Interleukin-11
Thrombopoietin
Cell culture
Albumins
Bone
Hemostasis
Platelet Count
Wound Healing
Blood Vessels
Cell Culture Techniques
Bone Marrow
Pharmacology

Keywords

  • Hematopoietic progenitor cells (HPCs)
  • Human induced pluripotent stem cells (hiPSCs)
  • Megakaryocytes (MKs)
  • Platelet

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Li, Y., Wang, Y., Cheng, L., & Wang, Z. Z. (2015). Derivation of megakaryocytes and platelets from human pluripotent stem cells. In Hematopoietic Differentiation of Human Pluripotent Stem Cells (pp. 41-50). Springer Netherlands. https://doi.org/10.1007/978-94-017-7312-6_3

Derivation of megakaryocytes and platelets from human pluripotent stem cells. / Li, Yanfeng; Wang, Ying; Cheng, Linzhao; Wang, Zack Z.

Hematopoietic Differentiation of Human Pluripotent Stem Cells. Springer Netherlands, 2015. p. 41-50.

Research output: Chapter in Book/Report/Conference proceedingChapter

Li, Y, Wang, Y, Cheng, L & Wang, ZZ 2015, Derivation of megakaryocytes and platelets from human pluripotent stem cells. in Hematopoietic Differentiation of Human Pluripotent Stem Cells. Springer Netherlands, pp. 41-50. https://doi.org/10.1007/978-94-017-7312-6_3
Li Y, Wang Y, Cheng L, Wang ZZ. Derivation of megakaryocytes and platelets from human pluripotent stem cells. In Hematopoietic Differentiation of Human Pluripotent Stem Cells. Springer Netherlands. 2015. p. 41-50 https://doi.org/10.1007/978-94-017-7312-6_3
Li, Yanfeng ; Wang, Ying ; Cheng, Linzhao ; Wang, Zack Z. / Derivation of megakaryocytes and platelets from human pluripotent stem cells. Hematopoietic Differentiation of Human Pluripotent Stem Cells. Springer Netherlands, 2015. pp. 41-50
@inbook{2ef8b67d0cff4450bcd3bcd955a54169,
title = "Derivation of megakaryocytes and platelets from human pluripotent stem cells",
abstract = "Megakaryocytes (MKs), rare hematopoietic cells in adult bone marrow, produce platelets that are critical to vascular hemostasis and wound healing. Ex vivo generation of MKs from human induced pluripotent stem cells (hiPSCs) provides a renewable cell source of platelets for treating thrombocytopenic patients and allows a better understanding of MK/platelet biology. The key requirements in this approach include developing a robust and consistent method for the production of functional progeny cells, such as MKs from hiPSCs, and minimizing risk and variation due to the animal-derived products in cell cultures. Here, we describe an efficient system to generate MKs from hiPSCs under a feeder-free and xeno-free condition, in which all the animal-derived products were eliminated. Several crucial reagents were evaluated and replaced with FDA-approved pharmacological reagents, including romiplostim (Nplate{\circledR}, a thrombopoietin analog), Oprelvekin (recombinant IL-11), and Plasbumin (human albumin). This basic and defined differentiation system provides a platform for our future effort in investigation of regulatory factors and protocol optimization toward generating large numbers of platelets ex vivo.",
keywords = "Hematopoietic progenitor cells (HPCs), Human induced pluripotent stem cells (hiPSCs), Megakaryocytes (MKs), Platelet",
author = "Yanfeng Li and Ying Wang and Linzhao Cheng and Wang, {Zack Z.}",
year = "2015",
month = "8",
day = "25",
doi = "10.1007/978-94-017-7312-6_3",
language = "English (US)",
isbn = "9789401773126",
pages = "41--50",
booktitle = "Hematopoietic Differentiation of Human Pluripotent Stem Cells",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Derivation of megakaryocytes and platelets from human pluripotent stem cells

AU - Li, Yanfeng

AU - Wang, Ying

AU - Cheng, Linzhao

AU - Wang, Zack Z.

PY - 2015/8/25

Y1 - 2015/8/25

N2 - Megakaryocytes (MKs), rare hematopoietic cells in adult bone marrow, produce platelets that are critical to vascular hemostasis and wound healing. Ex vivo generation of MKs from human induced pluripotent stem cells (hiPSCs) provides a renewable cell source of platelets for treating thrombocytopenic patients and allows a better understanding of MK/platelet biology. The key requirements in this approach include developing a robust and consistent method for the production of functional progeny cells, such as MKs from hiPSCs, and minimizing risk and variation due to the animal-derived products in cell cultures. Here, we describe an efficient system to generate MKs from hiPSCs under a feeder-free and xeno-free condition, in which all the animal-derived products were eliminated. Several crucial reagents were evaluated and replaced with FDA-approved pharmacological reagents, including romiplostim (Nplate®, a thrombopoietin analog), Oprelvekin (recombinant IL-11), and Plasbumin (human albumin). This basic and defined differentiation system provides a platform for our future effort in investigation of regulatory factors and protocol optimization toward generating large numbers of platelets ex vivo.

AB - Megakaryocytes (MKs), rare hematopoietic cells in adult bone marrow, produce platelets that are critical to vascular hemostasis and wound healing. Ex vivo generation of MKs from human induced pluripotent stem cells (hiPSCs) provides a renewable cell source of platelets for treating thrombocytopenic patients and allows a better understanding of MK/platelet biology. The key requirements in this approach include developing a robust and consistent method for the production of functional progeny cells, such as MKs from hiPSCs, and minimizing risk and variation due to the animal-derived products in cell cultures. Here, we describe an efficient system to generate MKs from hiPSCs under a feeder-free and xeno-free condition, in which all the animal-derived products were eliminated. Several crucial reagents were evaluated and replaced with FDA-approved pharmacological reagents, including romiplostim (Nplate®, a thrombopoietin analog), Oprelvekin (recombinant IL-11), and Plasbumin (human albumin). This basic and defined differentiation system provides a platform for our future effort in investigation of regulatory factors and protocol optimization toward generating large numbers of platelets ex vivo.

KW - Hematopoietic progenitor cells (HPCs)

KW - Human induced pluripotent stem cells (hiPSCs)

KW - Megakaryocytes (MKs)

KW - Platelet

UR - http://www.scopus.com/inward/record.url?scp=84956468629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956468629&partnerID=8YFLogxK

U2 - 10.1007/978-94-017-7312-6_3

DO - 10.1007/978-94-017-7312-6_3

M3 - Chapter

AN - SCOPUS:84956468629

SN - 9789401773126

SN - 9789401773119

SP - 41

EP - 50

BT - Hematopoietic Differentiation of Human Pluripotent Stem Cells

PB - Springer Netherlands

ER -